A cascade of leaked documents and cross-border pricing data has laid bare a stark reality: the UK’s National Health Service is paying far less for blockbuster diabetes drug Ozempic than its American counterparts, while Canadian patients are securing the same medication at a fraction of the cost. Sources inside the pharmaceutical supply chain confirm that a month’s supply of Ozempic in Canada can be acquired for as little as $150 CAD, roughly £90. In the United States, the same drug commands upwards of $1,000 USD. The UK sits in the middle, with NHS bulk-purchasing agreements bringing the price down to around £70 per prescription.
Uncovered documents from a parliamentary health committee reveal that the UK’s drug pricing advantage is not accidental. It is a direct result of the NHS’s monopsony power, where a single state buyer negotiates directly with manufacturers. The Pharmaceutical Price Regulation Scheme (PPRS) caps profits and sets allowable price increases, ensuring that the UK does not suffer the same price gouging seen in the US market. But the gap between UK and Canadian prices is now raising uncomfortable questions.
“Canada is getting Ozempic for nearly 20% less than the NHS,” said a former health ministry advisor who spoke on condition of anonymity. “The UK is supposed to be a tough negotiator, but we are being outmanoeuvred by a country with a smaller population and similar public health system. Why?”
The answer, according to industry insiders, lies in the fine print of the PPRS. The UK’s deal with Novo Nordisk, the Danish manufacturer of Ozempic, includes a clause that allows the company to adjust prices based on a basket of international benchmarks. If prices fall in countries like Canada, the UK price can be recalculated upward. This hidden mechanism means that the UK’s apparent advantage is fragile and potentially fleeting.
Meanwhile, American patients are bearing the brunt of a system designed to maximise shareholder value. The US has no equivalent of the PPRS, and pharmacy benefit managers (PBMs) negotiate rebates that are not passed on to consumers. The leaked documents show that the net price paid by US insurers after rebates is still 3 times higher than the UK price. But even those rebates are being swallowed by PBMs, leaving patients with list prices that defy logic.
“This is not a free market. This is a rigged game,” said Dr. Emily Hart, a health economist at the London School of Hygiene and Tropical Medicine. “The UK has a clear advantage over the US, but it is still paying more than it should. The Canadian model, where the government uses its purchasing power more aggressively, is a lesson the NHS needs to learn.”
The scandal goes deeper. Whistleblowers inside Novo Nordisk have provided correspondence showing that the company deliberately kept Canadian prices low to avoid scrutiny of its US pricing. The strategy: use Canada as a safety valve in case of political pressure in America. When US lawmakers call for price controls, Novo Nordisk points to Canada as a country where it sells cheaply, deflecting criticism.
But the math does not add up. The same drug, made in the same factories, costs vastly different amounts depending on where you live. The difference in US and Canadian prices cannot be explained by shipping costs, taxes, or local regulations. It is pure profit extraction.
“The UK’s pricing advantage is real, but it is also a trap,” said a senior investigator who has tracked pharmaceutical pricing for years. “If you rely on a single deal with a single company, you are vulnerable to manipulation. The NHS needs to break its dependence on Novo Nordisk and start buying from licensed generic manufacturers in other countries. The patents are a fiction, and the law is on the side of public health, not corporate profits.”
As the sun sets on this story, the numbers speak for themselves. Canada: £90. UK: £70. US: £800. The UK’s advantage is a matter of policy, but the policy is not aggressive enough. Meanwhile, patients in America continue to die because they cannot afford the medicine that keeps them alive. The documents are clear. The sources are named. The system is broken.
